A Dark Vector Cognition product

Item 1. Legal Proceedings

3K characters. Original on sec.gov ·

Item 1. Legal Proceedings

The 4 tables in Item 1. Legal Proceedings as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

​

Abbott is involved in various claims, legal proceedings and investigations as described in our Annual Report on Form 10-K for the year ended December 31, 2021, including (as of March 31, 2022, except where noted below) those described below. While it is not feasible to predict the outcome of such pending claims, proceedings and investigations with certainty, management is of the opinion that their ultimate resolution should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

​

In its 2021 Annual Report on Form 10-K, Abbott reported that it is a defendant in numerous lawsuits in federal and state courts involving certain of its specialty infant formula products administered to preterm infants. In April 2022, the U.S. Judicial Panel on Multidistrict Litigation ordered the consolidation of the federal court cases in the Northern District of Illinois for pretrial purposes.

​

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

​

(c)Issuer Purchases of Equity Securities

​

​​​​​​​​​​​​
​​​​​(d) Maximum
​​​​​​​​​Number (or
​​​​​​​(c) Total Number​Approximate
​​​​​​​of Shares (or​Dollar Value) of
​​(a) Total​​​​Units) Purchased​Shares (or Units)
​​Number of​(b) Average​as Part of​that May Yet Be
​​Shares (or​Price Paid per​Publicly​Purchased Under
​​Units)​Share (or​Announced Plans​the Plans or
Period​Purchased​Unit)​or Programs​Programs
January 1, 2022 – January 31, 2022​650,000(1) ​$127.262650,000​$5,998,449,112(2)​
February 1, 2022 – February 28, 2022​8,550,000(1)​​123.6438,550,000​​4,941,301,237(2)​
March 1, 2022 – March 31, 2022​8,113,060(1)​​118.3448,113,060​​3,981,169,070(2)​
Total​17,313,060(1)​$121.29617,313,060​$3,981,169,070(2)​
1.These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.

​

2.On October 11, 2019, the board of directors authorized the repurchase of up to $3 billion of Abbott common shares, from time to time (the “2019 Plan”). On December 10, 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott common shares, from time to time (the “2021 Plan”). The amount available for repurchase under the remaining portion of the 2019 Plan has been fully utilized as part of the share repurchases in the first quarter of 2022.

​

​

Previous: Item 4. Controls and Procedures · Next: Item 6. Exhibits